Olema Pharmaceuticals Inc - Asset Resilience Ratio
Olema Pharmaceuticals Inc (OLMA) has an Asset Resilience Ratio of 85.70% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read OLMA current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Olema Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Olema Pharmaceuticals Inc (OLMA) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Olema Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OLMA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $457.14 Million | 85.7% |
| Total Liquid Assets | $457.14 Million | 85.70% |
Asset Resilience Insights
- Very High Liquidity: Olema Pharmaceuticals Inc maintains exceptional liquid asset reserves at 85.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Olema Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Olema Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Olema Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Olema Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.70% | $457.14 Million | $533.43 Million | +20.37pp |
| 2024-12-31 | 65.33% | $294.61 Million | $450.98 Million | -4.46pp |
| 2023-12-31 | 69.79% | $193.27 Million | $276.94 Million | -14.02pp |
| 2022-12-31 | 83.80% | $180.72 Million | $215.65 Million | -8.59pp |
| 2021-12-31 | 92.39% | $273.44 Million | $295.94 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $342.72 Million | -- |
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive,… Read more